Business
Medincell to Present at the TD Cowen 46th Annual Healthcare Conference in Boston, March 2-4, 2026
MONTPELLIER, France, February 24, 2026--Regulatory News: Medincell (Euronext Paris: MEDCL), a commercial- and clinical-stage biopharmaceutical licensing company developing long-acting injectable treatments (the "Company"), today announced its participation at the TD Cowen 46th Annual Healthcare Conference, which will take place March 2-4, 2026 in Boston.
About this update from Medincell Sa
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1772,"height":295,"url":"https://media.zenfs.com/en/business-wire.com/c29244d468394aae7d28cec52b466659"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/IDBke8K.dUyTiu.aB_9Zvw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTE2MDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/c29244d468394aae7d28cec52b466659","width":960,"height":160},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/WBLk5hLczrMFTH8Z352U8g--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD00MDA7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/c29244d468394aae7d28cec52b466659","width":1200,"height":200}},"lazy":false},{"type":"text","content":"MONTPELLIER, France, February 24, 2026--(BUSINESS WIRE)--Regulatory News:","length":73,"tagName":"p"},{"type":"text","content":"Medincell (Euronext Paris: MEDCL), a commercial- and clinical-stage biopharmaceutical licensing company developing long-acting injectable treatments (the "Company"), today announced its participation at the TD Cowen 46th Annual Healthcare Conference, which will take place March 2-4, 2026 in Boston.","length":309,"tagName":"p"},{"type":"text","content":"The Company will present on Tuesday, March 3, 2026, at 1:50pm ET.","length":65,"tagName":"p"},{"type":"text","content":"Investor meetings with Dr Grace Kim, Chief Strategy Officer, U.S. Finance, may be arranged via TD conference coordinators or direct contact with Medincell.","length":155,"tagName":"p"},{"type":"text","content":"About Medincell","length":15,"tagName":"p"},{"type":"text","content":"Medincell is a clinical- and commercial-stage biopharmaceutical licensing company developing long-acting injectable treatments across multiple therapeutic areas. Our innovative treatments are designed to ensure adherence to medical prescriptions, enhance the effectiveness and accessibility of medicines, and reduce their environmental impact.","length":343,"tagName":"p"},{"type":"text","content":"These treatments combine active pharmaceutical ingredients with our proprietary BEPO® / BEPO® Star technologies, which enables controlled drug delivery at therapeutic levels for several days, weeks, or months following a subcutaneous or local injection of a small, fully bioresorbable deposit.","length":293,"tagName":"p"},{"type":"t...